Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 1, 2005, Pages 196-202

  Lamprecht, Alf ^a   Yamamoto, Hiromitsu ^b   Takeuchi, Hirofumi ^b   Kawashima, Yoshiaki ^b  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; MYELOPEROXIDASE; NANOPARTICLE; OXAZOLONE; TACROLIMUS; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CLINICAL FEATURE; CONTROLLED STUDY; DOSE CALCULATION; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG PENETRATION; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; EXPERIMENTAL INFECTION; LYMPHOCYTIC COLITIS; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; TISSUE DISTRIBUTION;

ANIMALS; COLITIS; CREATININE; DRUG DELIVERY SYSTEMS; MALE; NANOSTRUCTURES; OXAZOLONE; RATS; RATS, WISTAR; TACROLIMUS; TRINITROBENZENESULFONIC ACID;

EID: 25644442467     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.088146     Document Type: Article

References (36)

1. Aiko S, Conner EM, Fuseler JA, and Grisham MB (1997) Effects of cyclosporine or FK506 in chronic colitis. J Pharmacol Exp Ther 280:1075-1084.
2. Akashi T, Nefuji T, Yoshida M, and Hosoda J (1996) Quantitative determination of tautomeric FK506 by reversed-phase liquid chromatography. J Pharm Biomed Anal 14:339-346.
3. Allison MC, Cornwall S, Poulter LW, Dhillon AP, and Pounder RE (1988) Macrophage heterogeneity in normal colonic mucosa and in inflammatory bowel disease. Gut 29:1531-1538.
4. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, and Rutgeerts P (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348:601-608.
5. Boirivant M, Fuss IJ, Chu A, and Strober W (1998) Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 188:1929-1939.
6. Egan LJ and Sandborn WJ (1998) Drug therapy of inflammatory bowel disease. Drugs Today 34:431-446.
7. Ekström GM (1998) Oxazolone-induced colitis in rats: effects of budesonide, cyclosporin A and 5- aminosalicylic acid. Scand J Gastroenterol 33:174-179.
8. Farrell RJ and Kelleher D (2003) Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 178:339-346.
9. Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, Mahmud N, Keeling PW, Weir DG, and Kelleher D (2000) High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118:279-288.
10. Fellermann K, Ludwig D, Stahl M, David-Walek T, and Stange EF (1998) Steroidunresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 93:1860-1866.
11. Finn WF (1999) FK506 nephrotoxicity. Renal Failure 21:319-329.
12. Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182-205.
13. Florence AT, Hillery AM, Hussain N, and Jani PU (1995) Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J Drug Target 3:65-70.
14. Hartmann G, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, Tschoep K, Eigler A, Lehr HA, and Endres S (2000) Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharm Exp Ther 292:22-30.
15. Hoshino H, Goto H, Sugiyama S, Hayakawa T, and Ozawa T (1995) Effects of FK506 on an experimental model of colitis in rats. Aliment Pharmacol Ther 9:301-307.
16. Jubeh TT, Barenholz Y, and Rubinstein A (2004) Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm Res (NY) 21:447-453.
17. Kagayama A, Tanimoto S, Fujisaki J, Kaibara A, Ohara K, Iwasaki K, Hirano Y, and Hata T (1993) Oral absorption of FK506 in rats. Pharm Res (NY) 10:1446-1450.
18. Krawisz JE, Sharon P, and Stenson WF (1984) Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 87:1344-1350.
19. Lampen A, Christinas U, Gonschior AK, Bader A, Hackbarth I, von Engelhardt W, and Sewing KF (1996) Metabolism of the macrolide immunosuppressant, tacrolimus, by pig gut mucosa in the Ussing chamber. Br J Pharmacol 117:1730-1734.
20. Lamprecht A (2003) Multiparticulate systems in the treatment of inflammatory bowel disease. Curr Drug Targets Inflamm Allergy 2:137-144.
21. Lamprecht A, Schäfer U, and Lehr CM (2001a) Size dependent targeting of microand nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res (NY) 18:788-793.
22. Lamprecht A, Stallmach A, Kawashima Y, and Lehr CM (2002) Carrier systems for the treatment of inflammatory bowel disease. Drugs Future 27:961-971.
23. Lamprecht A, Ubrich N, Yamamoto H, Schäfer U, Takeuchi H, Lehr CM, Maincent P, and Kawashima Y (2001b) Design of rolipram loaded nanoparticles: comparison of two preparation methods. J Control Release 71:297-306.
24. Lamprecht A, Ubrich N, Yamamoto H, Schäfer U, Takeuchi H, Maincent P, Kawashima Y, and Lehr CM (2001c) Biodegradable nanoparticles for the targeted drug delivery in the treatment of inflammatory bowel disease. J Pharmacol Exp Ther 299:775-781.
25. Matsuhashi N, Nakajima A, Watanabe K, Komeno Y, Suzuki A, Ohnishi S, Omata M, Kondo K, Usui Y, Iwadare JI, et al. (2000) Tacrolimus in corticoid-resistant ulcerative colitis. J Gastroenterol 35:655-657.
26. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, and Wallace JL (1989) Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803.
27. Nakase H, Okazaki K, Tabata Y, Uose S, Ohana M, Uchida K, Matsushima Y, Kawanami C, Oshima C, Ikada Y, et al. (2000) Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J Pharmacol Exp Ther 292:15-21.
28. Nakase H, Okazaki K, Tabata Y, Uose S, Ohana M, Uchida K, Nishi T, Debreceni A, Itoh T, Kawanami C, et al. (2001) An oral drug delivery system targeting immuneregulating cells ameliorates mucosal injury in trinitrobenzene sulfonic acidinduced colitis. J Pharmacol Exp Ther 297:1122-1128.
29. Neurath MF, Fuss I, Kelsall BL, Stuber E, and Strober W (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182:1281-1290.
30. Pardridge WM (2002) Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1:131-139.
31. Seldenrijk CA, Drexhage HA, Meuwissen SG, Pals ST, and Meijer CJ (1989) Dentritic cells and scavenger macrophage in chronic inflammatory bowel disease. Gut 30:484-491.
32. Shimomura M, Masuda S, Saito H, Sakamoto S, Uemoto S, Tanaka K, and Inui K (2002) Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. J Surg Res 103:215-222.
33. Stärkel P, Sempoux C, Van Den Berge V, Stevens M, De Saeger C, Desager JP, and Horsmans Y (1999) CYP 3A proteins are expressed in human neutrophils and lymphocytes but are not induced by rifampicin. Life Sci 64:643-653.
34. Stein J, Ries J, and Barrett KE (1998) Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am J Physiol 274:G203-G209.
35. Tabata Y, Inoue Y, and Ikada Y (1996) Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 14:1677-1685.
36. Zhou SY, Fleisher D, Weiner N, and Zimmermann E (1999) Lumenal liposomes preferentially target drugs to inflamed intestinal tissue. Gastroenterology 116:A852-A852.